ZA200405345B - Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins. - Google Patents

Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins.

Info

Publication number
ZA200405345B
ZA200405345B ZA200405345A ZA200405345A ZA200405345B ZA 200405345 B ZA200405345 B ZA 200405345B ZA 200405345 A ZA200405345 A ZA 200405345A ZA 200405345 A ZA200405345 A ZA 200405345A ZA 200405345 B ZA200405345 B ZA 200405345B
Authority
ZA
South Africa
Prior art keywords
avermectins
ratio
streptomyces avermitilis
gene directing
avermitilis gene
Prior art date
Application number
ZA200405345A
Other languages
English (en)
Inventor
Kim Jonelle Sutzman-Engwall
Anke Krebber
Jeremy Stephen Minshull
Yan Chen
Claes Eric Daniel Gustafsson
Sun Ai Raillard
Seran Kim
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200405345B publication Critical patent/ZA200405345B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • C12P19/60Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C12P19/623Avermectin; Milbemycin; Ivermectin; C-076

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
ZA200405345A 2002-02-12 2004-07-05 Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins. ZA200405345B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35622202P 2002-02-12 2002-02-12

Publications (1)

Publication Number Publication Date
ZA200405345B true ZA200405345B (en) 2005-06-14

Family

ID=27734621

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200405345A ZA200405345B (en) 2002-02-12 2004-07-05 Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins.

Country Status (25)

Country Link
US (2) US7388085B2 (enExample)
EP (2) EP2050815B1 (enExample)
JP (1) JP2005517406A (enExample)
KR (1) KR100718378B1 (enExample)
CN (2) CN1630712B (enExample)
AR (1) AR038405A1 (enExample)
AT (2) ATE530645T1 (enExample)
AU (1) AU2003245052B2 (enExample)
BR (1) BRPI0307620B8 (enExample)
CA (1) CA2475214C (enExample)
CY (2) CY1110454T1 (enExample)
DE (1) DE60326824D1 (enExample)
DK (2) DK1476539T3 (enExample)
ES (2) ES2373629T3 (enExample)
IL (3) IL162866A0 (enExample)
ME (1) ME00472B (enExample)
MX (1) MXPA04007777A (enExample)
PL (1) PL211693B1 (enExample)
PT (2) PT1476539E (enExample)
RS (1) RS50813B (enExample)
RU (1) RU2293117C2 (enExample)
SI (2) SI1476539T1 (enExample)
TW (1) TWI341330B (enExample)
WO (1) WO2003068955A2 (enExample)
ZA (1) ZA200405345B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530645T1 (de) * 2002-02-12 2011-11-15 Pfizer Prod Inc Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine
CN102241750B (zh) * 2010-05-14 2014-05-28 中国科学院微生物研究所 一种生产阿维菌素的基因工程方法及其专用菌株
CN102093997B (zh) * 2010-12-01 2013-03-13 中国科学院上海有机化学研究所 一种改造除虫链霉菌产生多拉菌素的方法
CN109576196B (zh) * 2019-01-25 2022-01-04 北大方正集团有限公司 一种生产多拉菌素的发酵培养基及多拉菌素的生产方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4429042A (en) 1978-09-08 1984-01-31 Merck & Co., Inc. Strain of Streptomyces for producing antiparasitic compounds
IN167980B (enExample) 1987-01-23 1991-01-19 Pfizer
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
AU680039B2 (en) * 1993-10-05 1997-07-17 Pfizer Inc. Process and antiparasitic intermediates for doramectin
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
JP2002503473A (ja) * 1998-02-13 2002-02-05 ファイザー・プロダクツ・インク B2:b1アベルメクチンの比に関するストレプトミセス・アベルミティリス遺伝子
US6248579B1 (en) * 1998-02-13 2001-06-19 Pfizer Inc Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
RU2156301C2 (ru) * 1998-06-09 2000-09-20 Мосин Владимир Александрович Штамм актиномицета streptomyces avermitilis ссм 4697 - продуцент авермектинов
US6197591B1 (en) 1998-09-14 2001-03-06 Pfizer Inc. Streptomyces avermitilis regulatory genes for increased avermectin production
PT1200606E (pt) * 1999-08-12 2006-12-29 Pfizer Prod Inc Gene de streptomyces avermitilis que regula a proporção de avermectinas b2:b1
AR032130A1 (es) 1999-08-13 2003-10-29 Vertex Pharma Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto
ATE530645T1 (de) * 2002-02-12 2011-11-15 Pfizer Prod Inc Streptomyces avermitilis gen zur regulierung des verhältnisses der b2:b1 avermectine

Also Published As

Publication number Publication date
ME00472B (me) 2011-10-10
DE60326824D1 (de) 2009-05-07
WO2003068955A3 (en) 2003-11-13
KR100718378B1 (ko) 2007-05-14
TWI341330B (en) 2011-05-01
PT1476539E (pt) 2009-04-09
AR038405A1 (es) 2005-01-12
PL211693B1 (pl) 2012-06-29
ATE530645T1 (de) 2011-11-15
EP1476539B1 (en) 2009-03-25
EP1476539A2 (en) 2004-11-17
CA2475214A1 (en) 2003-08-21
US7388085B2 (en) 2008-06-17
CY1112491T1 (el) 2015-12-09
BRPI0307620B1 (pt) 2015-08-11
BR0307620A (pt) 2004-12-07
CN102392028B (zh) 2013-08-14
IL162866A0 (en) 2005-11-20
DK1476539T3 (da) 2009-05-11
JP2005517406A (ja) 2005-06-16
ES2373629T3 (es) 2012-02-07
PT2050815E (pt) 2012-01-02
AU2003245052A1 (en) 2003-09-04
CN102392028A (zh) 2012-03-28
IL192371A (en) 2010-11-30
BRPI0307620B8 (pt) 2016-09-13
KR20040081199A (ko) 2004-09-20
HK1074644A1 (en) 2005-11-18
WO2003068955A2 (en) 2003-08-21
PL371320A1 (en) 2005-06-13
CA2475214C (en) 2012-07-31
MXPA04007777A (es) 2004-10-15
SI1476539T1 (sl) 2009-06-30
IL162866A (en) 2009-11-18
CN1630712A (zh) 2005-06-22
RS50813B (sr) 2010-08-31
SI2050815T1 (sl) 2012-01-31
RU2293117C2 (ru) 2007-02-10
RU2004124521A (ru) 2005-04-10
EP2050815A1 (en) 2009-04-22
CN1630712B (zh) 2011-09-28
AU2003245052B2 (en) 2008-07-31
ATE426659T1 (de) 2009-04-15
DK2050815T3 (da) 2011-12-12
IL192371A0 (en) 2008-12-29
ES2321827T3 (es) 2009-06-12
TW200303918A (en) 2003-09-16
US8008078B2 (en) 2011-08-30
US20090017508A1 (en) 2009-01-15
HK1168383A1 (en) 2012-12-28
US20030166165A1 (en) 2003-09-04
CY1110454T1 (el) 2015-04-29
EP2050815B1 (en) 2011-10-26
RS70004A (sr) 2006-10-27

Similar Documents

Publication Publication Date Title
AU2002363246A1 (en) Game with multiple chambers
AU2003237249A1 (en) Oligonucleotides having modified nucleoside units
AU2003241621A1 (en) Oligonucleotides having modified nucleoside units
AU5515901A (en) Gamma-phosphoester nucleoside triphosphates
ZA200408568B (en) Clarithromycin formulations having improved biovailability.
SI1594878T1 (sl) Monosaharidni derivati avermektina s pesticidnimilastnostmi
AU2003238324A1 (en) Multiple game block assembly
IL147562A0 (en) Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
ZA991138B (en) Streptomyces avermitilis gene directing the ratio of B2: B1 avermectins.
ZA200405345B (en) Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins.
NO20020664L (no) Streptomyces Avermitilis gen som bestemmer forholdet B2:B1 avermectiner
EP1789430B8 (en) Derivates of avermectin,avermectin monosaccharide and avermectin aglycone
AU2002317415A1 (en) Azalide antibiotic compositions
AU2003258449A1 (en) Piercing projectile
AU2003304705A1 (en) 11-csubsituted erythromycin derivatives
AU2003285599A1 (en) Novel semisynthetic macrolide antibiotics of the azalide series
AU2003254555A1 (en) S. aureus antigene
SI1638984T1 (sl) Monosaharidni derivati avermektina B1
DK1200605T3 (da) Streptomyces avermitilis gen, der dirigerer forholdet imellem B2:B1 avermectiner
AUPR282501A0 (en) Expression facilitating nucleotides
AU2003234241A1 (en) Flutes with multiple chambers that share compound bisected toneholes
HK1071531A (en) Game with multiple chambers
AU2003900416A0 (en) Www.cashramspam.com
AU2003906259A0 (en) Lottery
AU2003900803A0 (en) Winners-m lottery